Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials

荟萃分析 抗精神病药 精神分裂症(面向对象编程) 期限(时间) 医学 精神科 心理学 心理治疗师 内科学 物理 量子力学
作者
Claudia Leucht,Stephan Heres,John M. Kane,Werner Kissling,John M. Davis,Stefan Leucht
出处
期刊:Schizophrenia Research [Elsevier]
卷期号:127 (1-3): 83-92 被引量:373
标识
DOI:10.1016/j.schres.2010.11.020
摘要

Non-adherence is a major problem in the treatment of schizophrenia. Depot antipsychotic drugs are thought to reduce relapse rates by improving adherence, but a systematic review of long-term studies in outpatients is not available.We searched the Cochrane Schizophrenia Group's register, ClinicalTrials.gov, Cochrane reviews on depot medication, and the reference sections of included studies for randomised controlled trials lasting at least 12 months in outpatients that compared depot with oral antipsychotics in schizophrenia. Data on relapse (primary outcome), rehospitalisation, non-adherence, and dropout due to any reason, inefficacy of treatment and adverse events were summarised in a meta-analysis using a random-effects model. Study quality was assessed with the Cochrane collaboration's risk of bias tool, and publication bias with funnel plots.Ten studies with 1700 participants met the inclusion criteria. Depot formulations significantly reduced relapses with relative and absolute risk reductions of 30% and 10%, respectively (RR 0.70, CI 0.57-0.87, NNT 10, CI 6-25, P=0.0009), and dropout due to inefficacy (RR 0.71, CI 0.57-0.89). Limited data on non-adherence, rehospitalisation and dropout due to any reason and adverse events revealed no significant differences. There were several potential sources of bias such as limited information on randomisation methods, problems of blinding and different medications in the depot and oral groups. Other studies reduced a potential superiority of depot by excluding non-adherent patients.Depot antipsychotic drugs significantly reduced relapse. Due to a number of methodological problems in the single trials the evidence is, nonetheless, subject to possible bias.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
orchid完成签到,获得积分10
3秒前
LIU完成签到,获得积分10
8秒前
Hello应助紧张的海露采纳,获得10
10秒前
英勇大神发布了新的文献求助10
10秒前
arong完成签到,获得积分10
13秒前
是我呀小夏完成签到 ,获得积分10
15秒前
17秒前
Dawn完成签到 ,获得积分10
17秒前
18秒前
情怀应助LIU采纳,获得10
21秒前
24秒前
evefei发布了新的文献求助10
29秒前
Kelly1426完成签到,获得积分10
37秒前
英勇大神完成签到,获得积分20
38秒前
Yang完成签到,获得积分10
38秒前
小叶完成签到 ,获得积分10
40秒前
领导范儿应助眼药水采纳,获得10
41秒前
xiaowei666完成签到,获得积分10
41秒前
nana完成签到,获得积分10
41秒前
CC完成签到,获得积分10
41秒前
evefei完成签到,获得积分10
41秒前
46秒前
英勇大神关注了科研通微信公众号
49秒前
赘婿应助科研通管家采纳,获得10
49秒前
benben055应助科研通管家采纳,获得10
49秒前
Orange应助科研通管家采纳,获得10
49秒前
汉堡包应助科研通管家采纳,获得10
50秒前
无花果应助科研通管家采纳,获得10
50秒前
秋雪瑶应助科研通管家采纳,获得10
50秒前
SciGPT应助科研通管家采纳,获得10
50秒前
Denmark完成签到 ,获得积分10
51秒前
51秒前
阿连完成签到,获得积分10
51秒前
cmwang发布了新的文献求助10
53秒前
futianyu完成签到 ,获得积分10
53秒前
小妮子完成签到,获得积分10
54秒前
眼药水发布了新的文献求助10
58秒前
猪小猪完成签到 ,获得积分10
1分钟前
DY应助意悟采纳,获得10
1分钟前
殷勤的幻丝完成签到,获得积分10
1分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2546270
求助须知:如何正确求助?哪些是违规求助? 2175702
关于积分的说明 5600512
捐赠科研通 1896445
什么是DOI,文献DOI怎么找? 946285
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557